A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
for Acute Myeloid Leukemia
Drug: Venetoclax
Sites in Houston +3 more locations
Sponsor: M.D. Anderson Cancer Center
Sex: All·Age: 12+
Code: NCT06284486·Phase 1, Phase 2·Recruiting·Listed Feb 2024